Monitor the execution of cost reduction initiatives ($2.5M annualized EBITDA savings expected) and track OEM Channel pricing stabilization. The CFO transition could create near-term uncertainty, but the reaffirmed guidance and commercial momentum suggest management confidence in 2026 recovery.
Price Chart
Executive Summary
Anika Therapeutics reported flat Q4 revenue of $30.6M but full-year 2025 revenue declined 6% to $112.8M, driven by a 17% drop in OEM Channel sales. The company reaffirmed 2026 revenue guidance of $114-122.5M and announced CFO David Colleran's planned departure in May 2026. Despite improved gross margins and strong commercial channel growth, the negative revenue trend and executive departure outweigh positive operational improvements.
Key Financial Metrics
Key Facts
- Q4 2025 revenue: $30.6M (flat YoY), full-year 2025 revenue: $112.8M (down 6% YoY)
- Commercial Channel revenue grew 22% in Q4 and 15% for full year 2025
- OEM Channel revenue declined 12% in Q4 and 17% for full year 2025 due to U.S. pricing pressures
- CFO David Colleran will depart in May 2026 after transition period
- Company reaffirmed 2026 revenue guidance of $114-122.5M (up 1-9% YoY)
- Generated $11.2M operating cash flow and $4.4M free cash flow for full year 2025
Financial Impact
Full-year revenue down $7.1M YoY, with $13.4M decline in OEM Channel partially offset by $6.3M increase in Commercial Channel
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Commercial Channel | $48.4M | +15.0% |
| OEM Channel | $64.4M | -17.0% |
Risk Factors
- Continued pricing pressure in U.S. OA Pain Management segment
- Leadership transition risk with CFO departure
- FDA approval timeline uncertainty for Hyalofast PMA and Cingal NDA
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-073401 |
| Document: d106406dex101.htm | 0001193125-26-073401 |
| Document: d106406d8k.htm | 0001193125-26-073401 |
| Document: 0001193125-26-073401-index-headers.html | 0001193125-26-073401 |
| Document: 0001193125-26-073401-index.html | 0001193125-26-073401 |
| Document: 0001193125-26-073401.txt | 0001193125-26-073401 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 29, 2026 9w ago | 8-K | $16.17 $21.68 | ▲ +34.08% | ▲ +29.06% | $19.10 (+18.12%) |
Jul 14, 2026 11w ago | 8-K | $15.93 $22.03 | ▲ +38.29% | ▲ +35.95% | $19.10 (+19.90%) |
Jun 23, 2026 14w ago | 8-K | $14.73 $15.01 | ▲ +1.90% | ▼ −0.03% | $19.10 (+29.67%) |
Jun 11, 2026 16w ago | Institutional Cluster | $14.72 $15.60 | ▼ −5.98% | ▼ −4.20% | $19.10 (−29.76%) |
Jun 8, 2026 16w ago | DEFA14A | $14.60 $16.03 | ▲ +9.79% | ▲ +8.16% | $19.10 (+30.82%) |
Jun 1, 2026 17w ago | DEFA14A | $14.63 $14.63 | · 0.00% | ▲ +1.30% | $19.10 (+30.55%) |
Apr 30, 2026 22w ago | Insider Cluster | $12.45 $14.90 | ▲ +19.68% | ▲ +14.71% | $19.10 (+53.41%) |
Apr 29, 2026 22w ago | 8-K | $12.39 $14.90 | ▲ +20.26% | ▲ +14.21% | $19.10 (+54.16%) |
Apr 28, 2026 22w ago | DEFA14A | $12.39 $14.90 | ▲ +20.26% | ▲ +14.21% | $19.10 (+54.16%) |
Apr 15, 2026 24w ago | Press Release | $15.39 $14.80 | ▼ −3.83% | ▼ −9.65% | $19.10 (+24.11%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access